Ataxia is typically defined as the presence of abnormal, uncoordinated movements. An unsteady, staggering gait is described as an ataxic gait because walking is uncoordinated and appears to be ‘not ordered’. Ataxia can also refer to a group of neurological disorders in which motor behavior appears uncoordinated.
Therapy for ataxic patients is multi-modal. Pharmacological treatment has been beneficial in a small number of patients with specific ataxias and further research is ongoing worldwide. Examples of treatable ataxias include those due to deficiencies of vitamin E or coenzyme Q10 and Episodic Ataxia Type 2 (EA2), in which episodes of cerebellar dysfunction are reduced by acetazolamide treatment.
The total prevalence was estimated at 13.9/100 000. Hereditary ataxia prevalence in the region was estimated at 6.5/100 000: 4.2/100 000 for autosomal-dominant and 2.3/100 000 for autosomal recessive, 0.15/100 000 for Friedreich’s ataxia and 0.4/100 000 for ataxia telangiectasia.